Glenmark Pharmaceuticals President, North America & Global API, Robert Matsuk, says the agreement for these ophthalmic products is aligned with the company’s strategy to strengthen its focus on complex generic formulations.
Glenmark Pharmaceuticals has launched Nourkrin Woman, a clinically-proven proteoglycan replacement formula, for normalising hair growth cycle, the company has said. The product will be exclusively marketed in India by Glenmark under a licensing agreement with Denmark-headquartered firm Pharma Medico, according to company executives.
Nourkrin Woman contains Marilex, which is based on a proprietary scientific formula, which helps normalise, support and maintain the hair growth cycle, the firm said. “It is rich in specific proteoglycans (PG) essential for hair follicle development and sits in between hair replacement therapies and health supplements which women use to balance their hormonal imbalances,” said Rajesh Kapur, Senior Vice-President – Sales and Marketing, Glenmark.
This will be available in the form of a tablet, needs to be consumed twice a day for six months and will be prescribed by dermatologists. According to Indian Journal of Clinical and Experimental Dermatology, 15.3 per cent of women in India reportedly suffer from hair loss.
Published on: March 7, 2018